Jacques Jolivet
pharmaceutical industry
Alethia Biotherapeutics
Canada
Biography
Jolivet brings to Alethia over 25 years of expertise as both a corporate executive as well as a practicing clinical oncologist. Prior to joining Alethia, Dr. Jolivet served as Senior Vice-President, Clinical Development at Aegera Therapeutics. Previously, he served as Director of Clinical Development, Oncology at Shire Pharmaceuticals and its predecessor, BioChem Pharma, where he played a key role in the development of Troxatyl. Dr. Jolivet maintains a clinical oncology practice at the Hematology and Medical Oncology department of the Hôtel Dieu Hospital of St.-Jerôme. Dr. Jolivet received his medical degree from l’Universite de Montreal, and completed his residency in internal medicine at the Royal Victoria Hospital. He completed a 3-year fellowship in anticancer drug pharmacology at the National Cancer Institute in Besthesda, MD. Dr. Jolivet led a research laboratory at the University of Montreal for 15 years, and has received numerous grants and awards for his research culminating in two issued US patents and more than 80 published papers.
Research Interest
Jolivet brings to Alethia over 25 years of expertise as both a corporate executive as well as a practicing clinical oncologist. Prior to joining Alethia, Dr. Jolivet served as Senior Vice-President, Clinical Development at Aegera Therapeutics. Previously, he served as Director of Clinical Development, Oncology at Shire Pharmaceuticals and its predecessor, BioChem Pharma, where he played a key role in the development of Troxatyl. Dr. Jolivet maintains a clinical oncology practice at the Hematology and Medical Oncology department of the Hôtel Dieu Hospital of St.-Jerôme. Dr. Jolivet received his medical degree from l’Universite de Montreal, and completed his residency in internal medicine at the Royal Victoria Hospital. He completed a 3-year fellowship in anticancer drug pharmacology at the National Cancer Institute in Besthesda, MD. Dr. Jolivet led a research laboratory at the University of Montreal for 15 years, and has received numerous grants and awards for his research culminating in two issued US patents and more than 80 published papers.
